Dauntless Pharmaceuticals Launches New Company
News Jul 24, 2015
Dauntless Pharmaceuticals, Inc. has announced the closing of a $12 million Series A financing. The Company was started by Joel F. Martin, PhD, Co-Founder, President and CEO, and Sofinnova Ventures, the sole institutional investor in the Series A financing.
Michael Powell, PhD, Sofinnova general partner, is a Co-Founder and will also serve as Chairman. David Kabakoff, PhD, Sofinnova executive partner, will also serve on the Company’s board of directors.
Dauntless will apply its experienced senior team and preclinical, clinical, and regulatory development capabilities to advance a select portfolio of product candidates through preclinical and human proof-of-concept clinical development.
A hand-picked team of seasoned biotech professionals have joined Dauntless with the objective of developing important medicines in a cost-effective and time efficient manner. Dauntless and Sofinnova Ventures are committed to funding additional attractive development programs.
“I am pleased to be launching Dauntless with accomplished veterans, financial resources, and our first product candidate,” said Joel Martin, PhD, President and CEO of Dauntless Pharmaceuticals. “We intend to leverage established industry relationships, experienced personnel, and our operational capabilities to execute clinical trials efficiently across multiple assets. We invite entrepreneurs and licensors to consider partnering with Dauntless as a way to achieve their drug development objectives. I am very gratified to once again have the support and insight of the Sofinnova team as we build this business.”
The Series A financing will fund the development of DP1038, a preclinical-stage drug for the potential treatment of endocrine cancers. DP1038 exploits patented technology developed by Aegis Therapeutics, LLC, a drug-delivery and drug-formulation company that has successfully licensed technology to leading pharmaceutical and biopharmaceutical companies.
News of the Aegis agreement was outlined in a separate press release which can be found on the Dauntless website www.dauntlessph.com.
Dr. Martin served most recently as the President and CEO of Cebix, Incorporated, a Phase 2b company in the Sofinnova Ventures portfolio. Prior to Cebix, he served as President and CEO of Altair Therapeutics, a Phase 2 asthma company which was acquired in 2010. Dr. Martin was also a partner at Forward Ventures from 2001 through 2008, where he led investments in neuroscience and oncology companies including Hypnion, Predix, and Cellective Therapeutics. Said Dr. Powell, “Joel Martin is a successful serial entrepreneur, venture investor, and respected leader of drug development. He brings critical, multidisciplinary capabilities as CEO. We are pleased to be launching Dauntless with Joel, and look forward to working together on additional programs.”
Dr. Martin was also co-founder and CEO of Quantum Dot Corporation (acquired by Life Technologies), a pioneer in nanotechnology applications in the life sciences, as well as co-founder and CEO of Argonaut Technologies, a chemistry automation company (formerly NASDAQ: AGNT), which was acquired by Biotage AB. Dr. Martin earned his PhD in Physical Chemistry from the University of California, San Diego, and holds MBA and BS degrees from the University of Michigan, Ann Arbor.
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Safety and Efficacy of MERS Treatment Confirmed in Phase I TrialNews
An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE